The Glaucoma Foundation in the US has created an award scheme for innovation and excellence in glaucoma, recognizing the contribution of individuals who have "played a unique and significant role in promoting the medicine and science of glaucoma".

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

Timolol, latanoprost, and the fixed combinations of latanoprost/timolol (Xalcom; Pfizer) and dorzolamide/timolol (Cosopt; Merck) have equal efficacy and tolerability as well as equal levels of patient satisfaction, according to a study published online, ahead of print, by Graefe's Archive for Clinical and Experimental Ophthalmology.

INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.

A survey, released by the global campaign, All Eyes on Glaucoma, has revealed that more than 8.4 million people in Asia will be blinded by glaucoma by 2010 if they do not undergo treatment.

Oxidative stress may play a role in the pathogenesis of primary open angle glaucoma (POAG), according to a study published in the June/July 2008 issue of the Journal of Glaucoma.

High caffeine intake is associated with an increased risk of high-tension primary open angle glaucoma (POAG) in subjects with a positive family history of glaucoma, according to a study published in the May 2008 issue of Investigative Ophthalmology & Visual Science.

A new study shows that costs associated with glaucoma will more than double by 2025.

OT134, a laser therapy for the reduction of intraocular pressure, has completed the follow-up period of its first human clinical study.